Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | ASPH | Q12797 | 2/20 | 0.44 |
| ▸ | KDM8 | Q8N371 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | NR1H4 | Q96RI1 | 6/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | COPS5 | Q92905 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12065727 | 0.85 | EPHX2 (0.46) | CA1CA2ASPHKDM8KDM4E | |
| SCHEMBL12065712 | 0.81 | CA1 (0.40) | CA1CA2NR1H4EPHX2RAB9A | |
| SCHEMBL12065465 | 0.75 | NR1H4 (0.45) | CA1CA2ASPHKDM8KDM4E | |
| SCHEMBL15033784 | 0.74 | CA1 (0.45) | CA1CA2ASPHKDM8KDM4E | |
| SCHEMBL14998844 | 0.73 | CA1 (0.46) | CA1CA2ASPHKDM8KDM4E | |
| SCHEMBL10231976 | 0.71 | NR1H4 (0.46) | CA1CA2ASPHKDM8NR1H4 | |
| SCHEMBL10230274 | 0.71 | NR1H4 (0.46) | CA1CA2NR1H4EPHX2RAB9A | |
| SCHEMBL15033676 | 0.67 | ASPH (0.44) | ASPHKDM8NR1H4EPHX2COPS5 | |
| SCHEMBL12065464 | 0.66 | MEN1 (0.42) | CA1CA2NR1H4EPHX2RAB9A | |
| SCHEMBL15119866 | 0.66 | RXRA (0.48) | RAB9AL3MBTL1COPS5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9018212-B2 | Pyridazine carboxamides as CCR2 receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-04-28 | — | — | US | disclosed |
| US-20140323492-A1 | CCR2 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-10-30 | — | — | US | disclosed |
| WO-2011147772-A1 | CCR2 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323492-A1 | CCR2 RECEPTOR ANTAGONISTS | CCR2, CCRL2, CCR1 | CA1 3854/4885CA2 851/4885ASPH 4012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.